Armata Pharmaceuticals (ARMP) 10-K2017 FY Annual report

Filed: 14 Mar 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abundant, acknowledged, aeruginosabiofilm, againstP, American, andClostridium, andEnterobacter, andKlebsiella, APACHE, aureusunder, bacteremia, battling, baumannii, BiomX, bioreactor, Blinsky, breast, cancelled, cardiac, clarification, COBRA, coma, comatose, compassionate, constituted, critical, critically, cybersecurity, deny, deployed, disaster, Dragon, EnBiotix, Epibiome, eradicatingin, ESKAPE, exciting, exhausted, exhaustive, exploratory, faecium, flat, flexibility, Gamida, GILTI, Houston, hundred, ill, implant, ineligible, inhalation, inhaled, inquiry, intermediate, interruption, Intralytix, intravenously, iNtRON, Jeremey, judged, Ladenburg, lieu, MDR, MDRA, Methodist, modulation, native, navigating, Navy, notification, offshore, orA, orC, orK, orP, path, PCAOB, PhageLux, Phagomed, Phi, planet, prosthetic, rare, recovery, regime, Reneo, repatriated, repatriation, repealing, repurchased, respond, responding, round, SAB, scoring, sea, seriousP, seriousS, Staphylococcal, surgery, tailored, targetingP, TechnoPhage, territorial, terrorist, Thalmann, timetable, top, trillion, Trump, unfamiliar, uninterrupted, unremitted, unresponsive, urgency, valve, vigorously, vulnerable

Removed: AATF, advancement, age, andC, andK, Avtotehna, belong, bid, category, CDI, CMC, cocktail, collection, compelling, concurred, confidentiality, confined, contractor, coordinator, count, covariance, created, customer, decreasing, Deed, deficiency, derived, deriving, descent, directed, dispositive, dissolution, doubtful, ear, ECDC, ending, escalating, estimation, EU, exhibit, exit, expended, father, feature, footnote, forfeiture, formation, freely, furniture, Germany, GI, Glasgow, grew, hospitalization, hour, IDSA, inclusive, induction, indwelling, insignificant, interpolation, investigator, Japan, Julian, Kirk, leasehold, legacy, LeicesterC, light, liquidation, load, loan, MHRA, MKT, move, nasal, North, notoriously, obstructive, ofC, orderly, OTCQB, outin, partly, PCT, peer, Pennsylvania, placebo, predominant, preference, prepaid, prevalent, pronouncement, pulmonary, Randal, ranging, receivable, rendered, repaid, repayment, restatement, satisfied, securing, sensitivity, Smithyman, solid, sought, SPH, SSI, Subtopic, suited, sum, superficial, suppurative, suspended, technique, terminable, threatening, tiered, toxin, urgent, utilize, VABP, ventilator, Warranty, winding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ARMP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

AMPLIPHI BIOSCIENCES CORPORATION

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Paul C. Grint, M.D., Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: March 14, 2018

/s/ Paul C. Grint, M.D.

Paul C. Grint, M.D.

Chief Executive Officer

(Principal Executive Officer)